Tmj Treatment denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for tmj treatment are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny TMJ Treatment as Not FDA-Approved

Temporomandibular joint (TMJ) disorders are managed through a spectrum of interventions — from conservative physical therapy and oral appliances to injectable agents and surgical procedures. Cigna may issue a "not FDA-approved" denial when the specific treatment your provider selected either lacks FDA clearance or approval for the TMJ indication, or when a device bears only a narrow clearance that Cigna interprets as excluding your prescribed use. This is one of the most technically complex denial types because FDA device and drug pathways differ, and payers sometimes apply drug-approval logic to devices.

## Why This Denial Is Appealable

FDA clearance (510(k)) and FDA approval are distinct pathways, and many legitimate TMJ devices reach patients through the clearance route — which does not mean they are unapproved for clinical use. Your prescriber can document the regulatory status of the specific product and explain how its cleared indication covers your clinical situation. Additionally, if your insurer is an employer-sponsored ERISA plan, it must provide a full-and-fair review under ERISA §503. If it is an ACA-regulated plan, you have the right to an independent external review under ACA §2719 — typically with a filing window of approximately four months from the denial notice.

## The Appeal Process and Timeline

1. Request the denial in writing with the specific regulatory basis cited. 2. File an internal appeal within the deadline on your Explanation of Benefits (EOB) — usually 180 days. 3. If the internal appeal fails, request external review through your state's insurance commissioner or the federal external review process. External reviewers are independent of Cigna. 4. Expedited review is available if your condition is urgent or if a standard timeline would seriously jeopardize your health.

## Documentation to Gather

• Diagnosis confirmation: Imaging, examination findings, and any specialist evaluation confirming the TMJ diagnosis and severity.
• Regulatory documentation: The FDA clearance or approval letter and indication language for the specific product, obtained from your provider or the manufacturer.
• Medical-necessity letter: A signed letter from your prescriber explaining why this specific treatment is appropriate for your clinical situation and how the product's regulatory status supports its use.
• Treatment history: Records of any prior conservative treatments tried, with dates and documented outcomes, to demonstrate the clinical pathway that led to this intervention.

## Criteria-Mapping Structure

Obtain Cigna's published coverage policy for TMJ treatment from Cigna's website or by requesting it directly. For each coverage requirement listed, document the corresponding fact from your chart. For the FDA-status requirement specifically, match the exact regulatory language in Cigna's policy to the device or drug's actual FDA classification. Where the policy language is ambiguous, your prescriber's letter should address that ambiguity directly.